Key facts
- CellArk Bio’s last known valuation is $67.8M (Mar 2025).
- It has raised $40.1M; the latest was Early Stage VC in Mar 2026.
- Notable investors include Highlight Capital, TKG Ventures, BNH Investment, Korea Omega Investment, LSK Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for CellArk Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for CellArk Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CellArk Bio
Developer of a cell regeneration technology designed to promote youth and beauty. The company's technology specializes in building a sustainable aesthetic market to improve the quality of human life through quality management and creates cosmetic medical devices and pharmaceuticals using tissue engineering technology, enabling youth to get safe, natural, and pain-free treatment.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2024
- Employees
- 49
- Website
- cellarkbio.com/
- Ownership
- Privately Held (backing)
CellArk Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellArk Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellArk Bio in its N-PORT filings yet. We sweep new filings monthly.